Bio-Techne CEO to Present at 2026 J.P. Morgan Healthcare Conference on January 13
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Source: PRnewswire
- Conference Appearance: Bio-Techne's CEO Kim Kelderman will present at the 2026 J.P. Morgan Healthcare Conference on January 13 at 9:00 a.m. PST, showcasing the company's latest advancements in life sciences, which is expected to attract attention from investors and industry experts.
- Company Background: Bio-Techne is a global life sciences company providing innovative tools and bioactive reagents, generating over $1.2 billion in net sales for fiscal 2025, demonstrating its strong market position in biological research and clinical diagnostics.
- Product Portfolio: With hundreds of thousands of products, the company supports scientific investigations and drug discovery, aiding scientists in understanding biological processes and the progression of specific diseases, further solidifying its leadership in the industry.
- Employee Scale: Bio-Techne employs approximately 3,100 people worldwide, reflecting its extensive influence and ongoing growth potential in the life sciences sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TECH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TECH
Wall Street analysts forecast TECH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECH is 66.14 USD with a low forecast of 60.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 65.560
Low
60.00
Averages
66.14
High
72.00
Current: 65.560
Low
60.00
Averages
66.14
High
72.00
About TECH
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bio-Techne Launches Ultra-Sensitive Assays for Neurodegenerative Research
- Technological Innovation: Bio-Techne's launch of Simple Plex ultra-sensitive assays on the Ella automated platform significantly enhances the detection sensitivity of key biomarkers like NFL, GFAP, pTau 217, and Amyloid β (aa1-42), advancing early detection of neurodegenerative diseases.
- Research Applications: This new technology enables researchers to detect subtle biological changes that were previously difficult to identify, thereby accelerating insights into disease onset, progression, and treatment responses, enhancing the efficiency and accuracy of clinical research.
- Automation Advantages: The automated workflow of the Ella platform reduces overall runtime for assay results to under three hours, minimizing manual steps and variability, ensuring the reliability of ultra-sensitive results, and further solidifying Bio-Techne's leadership in the immunoassay market.
- Market Impact: With over $1.2 billion in net sales for fiscal 2025, this technology release is expected to further drive breakthroughs in neuroscience research and precision medicine, enhancing the company's competitiveness in the life sciences tools market.
Continue Reading
Bio-Techne Launches Ultra-Sensitive Detection Technology
- Ultra-Sensitive Detection: Bio-Techne launches Simple Plex ultra-sensitive assays on the Ella platform, enabling detection of neurodegenerative disease biomarkers at femtogram concentrations in blood, significantly enhancing early disease insight capabilities.
- Automated Workflow: The new automated immunoassay workflow reduces total runtime to under three hours, minimizing manual steps and variability, thereby improving result reliability and reproducibility to support high-throughput studies.
- Research Support: This technology supports research in Alzheimer's, ALS, MS, Parkinson's Disease, and Traumatic Brain Injury, allowing for earlier identification of biological changes and accelerating insights into disease progression and treatment responses.
- Market Leadership: By combining ultra-sensitive proteomic assays with automated instrumentation, Bio-Techne strengthens its leadership in the immunoassay market, driving breakthroughs in neuroscience research and advancing precision medicine.
Continue Reading